Berlex Yasmin 28
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Oral contraceptive clears FDA May 11. The product contains ethinyl estradiol and drospirenone as the progestin. According to Berlex parent Schering AG, "drospirenone is different from the progestins currently available" in other OCs, as it has "mild anti-mineralocorticoid activity" that can "counteract estrogen-based water retention in the body." Labeling includes a bolded warning on the potential for hyperkalemia in high-risk patients
Oral contraceptive clears FDA May 11. The product contains ethinyl estradiol and drospirenone as the progestin. According to Berlex parent Schering AG, "drospirenone is different from the progestins currently available" in other OCs, as it has "mild anti-mineralocorticoid activity" that can "counteract estrogen-based water retention in the body." Labeling includes a bolded warning on the potential for hyperkalemia in high-risk patients. |